Cancer is the second leading cause of death in Germany. In the search for new therapeutic approaches that target the uncontrolled growth of tumor cells, a class of enzymes known as cyclin-dependent kinases (CDKs) has come into focus. This is because this family of enzymes plays a fundamental role in gene expression and cell division. An overview of the current state of research on the transcriptional regulation of CDKs and the prospects for cancer treatment was compiled by Prof. Matthias Geyer of the University Hospital Bonn and the University of Bonn in collaboration with Prof. Robert P. Fisher of the Icahn School of Medicine at Mount Sinai, New York, and has now been published in Nature Reviews Drug Discovery.

Researchers at the University Hospital of Bonn (UKB) and the University of Bonn have identified a previously unknown signaling pathway in the immune system that helps newborn heart cells survive and regenerate after injury. The findings could open new avenues for future therapies aimed at repairing damaged adult hearts after heart attacks or chronic cardiovascular disease. The study has now been published in the journal Cell Communication and Signaling (Springer Nature).

Macrophages formed in the bone marrow can only assume the function of embryonal phagocytes, or “scavenger cells,” to a certain degree according to a study by the University of Bonn and the Peter Doherty Institute for Infection and Immunity at the University of Melbourne. The researchers have demonstrated that malaria infection causes permanent damage to resident CD163 macrophages in the spleen, which are responsible for cleaning the blood, recycling iron and communicating with other cells involved in the body’s immune response. Their findings could harbor potential not only for more effective malaria vaccines but also for developing drugs and treatments to combat other infectious diseases. The paper is to be published in the journal “Immunity” but can already be accessed online.

Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs. Researchers at the University Hospital Bonn (UKB) and the University of Bonn have now developed Core2Edge, a model based entirely on human tissue that captures these hard-to-access infiltration zones at the tumor margin. The model enables investigation of the invasive front and direct assessment of new drug candidates in human tissue - without the need for animal testing. The study of the Brain Tumor Translational Research Group has now been published in Nature Protocols.

In what will go down as an outstanding success for the University of Bonn’s Faculty of Medicine, Professor Frank G. Holz—Director of the Ophthalmology Clinic at the University Hospital Bonn and a professor at the University—has been shortlisted for the “Falling Walls Science Breakthrough of the Year 2026” in the Life Sciences category. His project thus ranks among the year’s top 30 scientific innovations in this category according to the prestigious Falling Walls Science Summit. Even making it onto the shortlist is a sign of significant international acclaim. The winners in the individual categories will be crowned at the Falling Walls Science Summit in Berlin from November 6 to 11.

B-cell depletion therapies, in which B cells of the immune system, which may drive disease activity in multiple sclerosis (MS), are temporarily removed, have contributed significantly to improved treatment for patients in recent years. Researchers from the University Hospital of Bonn (UKB), the Universities of Bonn, Basel, Toronto, and Yale, along with their collaborators, have uncovered a previously unknown mechanism through which B-cell depletion therapies contribute to a better disease course in patients with MS. Surprisingly, the treatment appears to exert part of its beneficial effect by mobilizing regulatory immune cells that naturally reside in the gut. This study has now been published in the journal Science Translational Medicine.

A team from the University of Bonn and the Research Center Borstel, Leibniz Lung Center (FZB) has discovered a previously unknown mechanism of action for a synthetic peptide that mitigates excessive inflammatory responses in allergic asthma. This mechanism specifically inhibits a key inflammatory switch in the immune system and opens up new avenues for treating chronic inflammatory diseases. The findings have now been published in the journal Advanced Science.

Interferon alpha is an inflammatory mediator that can cause Sjögren’s syndrome, an autoimmune disease. This is revealed in a recent study carried out by the University Hospital Bonn together with the University of Bonn, the University of Edinburgh and Newcastle University. Their findings, which have been published in the journal “Lancet Rheumatology,” could make it easier in the medium term to develop drugs to fight this chronic condition.